Drug Supply Of Patients Research Articles

Опыт лечения больных хронической ВГС‑инфекцией пангенотипной комбинацией препаратов прямого противовирусного действия (глекапревир/пибрентасвир) в Ставропольском крае

Objective. To analyze the results of usage of pangenotype combination glecaprevir/pibrentasvir (GLE/PIB) in real clinical practice in Stavropol Krai within the framework of the regional program on chronic hepatitis C (CHC) treatment. Materials and methods. In the framework of this study, a retrospective analysis of the use of GLE/PIB combination in the period from 2018 to 2022 within the framework of the regional program for the treatment of CHC in the Stavropol region was carried out. The drug was prescribed in accordance with the current label approved in Russia. Patients were observed during the entire period of GLE/PIB therapy and for 12 weeks after treatment completion. Data for analysis were collected from outpatient records and protocols of the “Regional Medical Commission on Diagnosis, Treatment and Drug Supply of Patients with Chronic Viral Hepatitis B and C in Stavropol Krai”. Results. The analysis included 405 patients treated within the framework of the regional program on drug supply of patients with chronic viral hepatitis B and C in the territory of the Stavropol region. The scope of the examination allowed to assess the sustained virologic response 12 weeks after the end of GLE/PIB therapy (SVR12). 92.6% (375/405) of patients had not previously received antiviral therapy. Absence or minimal manifestations of hepatic fibrosis (F0-1) were noted in 50.9% of patients, advanced stage of fibrosis (F3-4 by METAVIR scale) in 34.6%. The distribution by fibrosis stage was as follows: F0 – 21.98% (89/405), F1 – 28.9% (117/405), F2 – 14.6% (59/405), F3 – 13.1% (53/405), F4 (CP-A) – 21.5% (87/405). All patients with liver cirrhosis had compensated stage of the disease – class A according to Child-Pugh. In the study population, genotype (Gt) 3 prevailed, detected in 55.1% (223/405) of patients. Hepatitis C virus (HCV) Gt1 was diagnosed in 29.4% (119/405) of patients. Among them, 16.5% (67/405) of patients had Gt1b, 0.5% (2/405) had Gt1a, and 12.3% (50/405) of patients with Gt1 had no subtype identified. Gt2 was detected in 11.4% of patients (46/405), 3 (0.7%) patients had a genotype other than 1–3, and 14 (3.5%) patients had no HCV genotype determined. 14 (3.6%, 14/405) patients were co-infected with HCV and HIV. 23.5% (95/405) of patients belonged to the age group older than 60 years. The distribution of patients according to the duration of antiviral therapy was as follows: 8 weeks – 89.4% (362/405), 12 weeks – 6.4% (26/405) and 16 weeks – 4,2% (17/405). 405 (100,0%) out of 405 patients achieved SVR12. There were no cases of serious adverse events and treatment withdrawal during antiviral therapy. Conclusion. GLE/PIB has demonstrated high efficacy in patients with different HCV genotypes (including Gt3) and different stages of liver fibrosis (including compensated cirrhosis) in the real-world setting. The SVR12 rate obtained in this analysis is fully consistent with the data of clinical trials and real clinical practice published earlier. Key words: chronic hepatitis C, glecaprevir/pibrentasvir, pangenotypic, real clinical practice

Drug Supply for Patients With Epilepsy Under the Program of State Guarantees in the Kyrgyz Republic

The article presents the results of the analysis of drug provision for patients with epilepsy in Kyrgyzstan under the preferential program of state guarantees within the framework of compulsory medical insurance. The purpose of the study: analysis of preferential drug provision for patients diagnosed with epilepsy in the Kyrgyz Republic. Materials and research methods. Research materials: information data of the Compulsory Medical Insurance Fund under the Ministry of Health of the Kyrgyz Republic. Research methods: content analysis, graphical and statistical methods. Research results. As a result of the analysis of preferential drug provision for patients with epilepsy in the Kyrgyz Republic, data were obtained on assessing the availability of drug therapy for patients in this group. Patients diagnosed with epilepsy in 2022 received a total of 37,616 prescriptions for a reimbursement of about 16.8 million soms. When comparing data with 2021, the number of prescriptions issued to patients diagnosed with epilepsy in 2022 increased by 7485 prescriptions nationwide, and the amount of reimbursement increased by 12.7%. The main number of preferential prescriptions for the analyzed period was issued to the category of insured citizens, persons with disabilities, disabled people. The largest number of preferential prescriptions for patients diagnosed with epilepsy was issued in the southern region of the country - in Osh and Jalal-Abad regions.

ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)

to estimate the quality and availability of medical care for patients with ulcerative colitis (UC) and Crohn's disease (CD), to assess the impact of the economic burden of these diseases on the healthcare budget of Russia and to systematize the main problems in the organization of medical care and drug supply for patients with inflammatory bowel diseases (IBD). Regional IBD databases (2016-2018), official statistical databases, costs of treatment and results of expert interviews with specialists in IBD were used in the study. The analyzed databases showed 104,668 patients with UC in Russia in 2018 (prevalence rate 71 per 100,000 people) and 66,647 patients with CD (prevalence rate of 45 per 100,000 people). The economic burden including agents for biologic therapy (ABT) for the UC was 39.54 billion rubles a year (495 rubles per capita), and CD - 32.98 billion rubles a year (378 rubles per capita). It requires an additional 9.87 billion rubles annually for UC and 9.20 billion rubles annually for CD patients to provide the complete supply with ABT. The annual burden of IBD is 72.52 billion rubles, which is comparable to the costs of other socially significant diseases, including malignant tumors. It shows the high social and economic value of IBD for the country. The main problems of medical care and drug supply for IBD patients are the mismatch of official statistical data and real IBD prevalence in Russia due to absence of comprehensive register and the insufficient supply with ABT due to limited funding. A federal center for IBD should be founded for better quality of registration, for the precise monitoring and for the active management of personal drug supply.

ASSESSMENT OF THE ECONOMIC EFFICIENCY OF THE DRUG SUPPLY STRATEGY FOR PATIENTS WITH HEPATITIS C IN THE CITY OF MOSCOW

Evaluate the cost-effectiveness of various options for the supply of direct antiviral agents for patients with chronic viral hepatitis C. An analysis of the data of Moscow Department of Health on the drug supply of patients with chronic hepatitis C antiviral drugs at the expense of budgetary funds in Moscow was carried out. The direct medical costs of the urban healthcare system for the use of direct antiviral action drugs for the period from 2017 to 2019 were calculated. For the period from 2017 to 2019, 6,936 patients with chronic hepatitis C received medication with antiviral drugs at the expense of budget funds in Moscow. An increase in the number of patients compared to the base (2017) year was noted by 76%, as well as an increase in the volume of interferon-free antiviral therapy sets against the background of an increase in budget expenditures by 212%. The average level of cost for all sets with direct antiviral drugs amounted to 689,844 rub. The most commonly used set is Dac + Asu. The average cost of this set per patient treated as part of the first-line antiviral therapy was 58,899 rub. cheaper than a set of 3D, and 58,861 rub. more expensive than the Grz/Elb set, while the need for retreatment for the Dac + Asu set was 8.4%, and for the 3D, Grz/Elb and Gle/Pib sets, 0.58%, 0% and 0%, respectively. An even greater excess of the average was recorded for the Sof + Dac, Sof + Sim sets: which naturally entailed the excess of the costs of treating one patient with this distribution of treatment sets and financial resources by 253,236 rub. and 189,173 rub., respectively, which is 1.36 and 1, 27 times the average cost of all prices for antiviral treatment sets. Most often, re-medication was provided to patients who were initially provided with Sof set (33%), followed by Sim + Dac set (18.6%), 8.4% of re-medication cases were registered in patients who received Dac + Asu set as the first line of therapy. Budget costs for the second and subsequent sets of therapy increased by 92,739,115.30 rub.

Substantiation and development of the economic-mathematical model of rational drug provision for certain categories of citizens attached to military medical organizations

In modern socio-economic conditions, the maximum efficiency of the use of funds allocated from budgets of different levels to finance federal, regional and departmental programs for providing medicines is required. In connection with it, there is a need to justify and develop a model of rational drug supply for certain categories of citizens attached to military medical organizations that will visually reflect the functioning of military and civilian health in a single organizational and legal space, with the elimination of duplication of functions and powers of government. Approaches to the development of a model of rational drug provision are substantiated, while modeling the mathematical apparatus of Petri nets. A characteristic of the existing model of drug supply based on Petri nets for certain categories of citizens attached to military medical organizations is presented. The irrationality of the existing order of drug provision is proved, which results in an increase in the resource burden on public health in general. The model of rational drug supply of patients attached to military medical organizations that excludes duplication of provision of medicines by citizens within the framework of military and civil health is substantiated and developed; optimizes the distribution of rights, powers and responsibilities between military and civil health; ensures the coherence of military and civil health activities in the provision of medicines on the basis of information interaction; contributes to the preservation of financial, information and material resources in public health, as well as their balanced and rational use.

Marketing analysis of some groups antidiabetic medicines, presented at pharmaceutical market of Ukraine

The scarcity of state resources, the social economic and demographic situation, the deterioration of health status of population require new state approaches of organizing medical and pharmaceutical provision for the population. The aim of the study is the drug supply for patients with type ІІ diabetes. Relevance of theme is determined by the prevalence of the disease, the development of complex concomitant diseases, complications, early disability and high mortality due to low-quality and untimely medical and pharmaceutical care for this category of patients.
 The object of marketing research was the drugs registered in Ukraine, which cost is the subject to reimbursement for outpatient treatment of patients with type ІІ diabetes by the conditions of March 2017. The search for the proposals of drugs under study on the website of Morion Company was also conducted to assess the real state of the pharmaceutical market on this issue. The main used methods are bibliographic, statistical, marketing, graphic and systematization.
 The Ukrainian pharmaceutical market of drugs with the cost, which is the subject to reimbursement for outpatient treatment of patients with type II diabetes, has been investigated, and found that Gliclazide and Metformin are registered on the territory of Ukraine in the form of 22 and 91 medicines, respectively. The part of domestic producers of Gliclazide and Metformin is 36% and 33%, respectively.
 It was revealed, that the assortment of drugs Gliclazide and Metformin, which are available in the pharmacy network, is 2 and 1.4 times less than registered in Ukraine, respectively.
 Gliclazide and Metformin tablets are offered by domestic and foreign manufacturers in a dosage of 30 mg, 60 mg, 80 mg and 500 mg, 800 mg, 1 000 mg, respectively.

Organization of Medical Care and Drug Supply for Patients with Osteogenesis Imperfecta in the Republic of Bashkortostan

научный биометрический журнал, который знакомит читателя с клиническими рекомендациями и особенностями применения лекарственных и вакцинных средств у детей, предоставляет исчерпывающую информацию о воздействии лекарственных средств на плод, о проводимых в

Features of the organization of drug supply for patients with diabetes mellitus in Kazan

In recent years, the pharmacy service of the Republic of Tatarstan has undergone significant structural and qualitative changes, which are caused by the beginning processes of denationalization and privatization. As a result, many pharmacies acquired the status of a legal entity, including pharmacy No. 350 in Kazan.

Organization of drug supply for patients with neuropsychological rehabilitation in the context of the transition to market relations

In the Republic of Tatarstan, at present, the provision of medicines and medical products is mainly carried out by the state enterprise "Tatar stan pharmacy", which includes the republican pharmacy base, the Center for Controlling the Production and Quality of Medicines, the Republican Information Center, and a reference and information service for the population (003), as well as 298 self-supporting pharmacies, including 193 rural, 5 interhospital, 3 hospital pharmacies.